Neha Patil

Acadia Pharmaceuticals

Updated on
Share on FacebookTweet on TwitterShare on LinkedIn
Type  Public
Key people  Stephen R. Davis CEO
Revenue  $42.13M (2011)
Founded  1993
Traded as  NASDAQ: ACAD
Products  Pimavanserin
Number of employees  95
Acadia Pharmaceuticals wwwacadiapharmcomwpcontentthemesacadiaimag
Industry  Biopharmaceutical, Healthcare
Stock price  ACAD (NASDAQ) US$ 38.11 -1.74 (-4.37%)28 Feb, 4:00 PM GMT-5 - Disclaimer
Headquarters  San Diego, California, United States

acad acadia pharmaceuticals inc


ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase IV development as a treatment for Parkinson's disease psychosis. It is also developing AGN XX/YY, a product candidate in Phase II for chronic pain; and AC-262271, a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as AM-831, a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha. The product candidates in the company'’s pipeline emanate from discoveries made using its proprietary drug discovery platform.

Contents

Da approves acadia pharmaceuticals nuplazid pimavanserin


Recent Events

Acadia Pharmaceuticals extended its drug discovery and development research agreement with Allergan to March 2012. The agreement stipulates both parties will work together for the discovery of new therapeutics for glaucoma and ophthalmic conditions.

References

Acadia Pharmaceuticals Wikipedia


Similar Topics
Only 38
Henry E. Brown Jr.
Renjith Menon
Topics